(Q52962361)

English

Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma.

scientific article published in May 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

Initially metastatic breast carcinoma has a distinct disease pattern but an equivalent outcome compared with recurrent metastatic breast carcinoma. (English)

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

breast carcinoma

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

author name string

Antonio Jimeno

1

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

María Luz Amador

2

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

Lucía González-Cortijo

3

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

María Victoria Tornamira

4

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

Santiago Ropero

5

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

Vicente Valentín

6

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

Javier Hornedo

7

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

Hernán Cortés-Funes

8

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

language of work or name

0 references

publication date

1 May 2004

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

100

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

1833-1842

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

9

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

Differences in breast cancer stage, treatment, and survival by race and ethnicity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Construction and validation of a practical prognostic index for patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Steroid-hormone receptors and survival after first relapse in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Multivariate analysis of prognostic factors in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Ten-year outcome after combined modality therapy for inflammatory breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Differences in stage and therapy for breast cancer across Europe

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Influence and significance of certain prognostic factors on survival in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival after first recurrence of breast cancer. The Miami experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

Age as a prognostic factor in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen Receptor and Natural Course of Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and validation of prognostic models in metastatic breast cancer: a GOCS study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20204

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20204

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

1 reference

Europe PubMed Central

9 May 2018

http://europepmc.org/abstract/MED/15112263

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52962361&oldid=1524816292"